Search research articles
Contact Us
Filters
Showing results (21-30 of 629) with videos related to
Page
of 63
Sort By:
European Urology
|
December 22, 2011
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
Hans-Peter Schmid, Robert Theiler
The New England Journal of Medicine
|
April 15, 2026
Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply
Sara M Tolaney, Peter Schmid
The New England Journal of Medicine
|
May 4, 2022
Pembrolizumab in Early Triple-Negative Breast Cancer. Reply
Peter Schmid, Javier Cortes, Rebecca Dent
Current Cancer Drug Targets
|
February 9, 2017
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Karen O'Leary, Alice Shia, Peter Schmid
The New England Journal of Medicine
|
March 12, 2025
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply
Peter Schmid, Xuan Zhou, Rebecca Dent
The New England Journal of Medicine
|
June 25, 2020
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply
Peter Schmid, Rebecca Dent, Joyce O'Shaughnessy
Translational Andrology and Urology
|
January 28, 2016
Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
Johannes M Wolff, Hans-Peter Schmid
Immunology and Allergy Clinics of North America
|
November 26, 2016
Allergic Skin Diseases
Peck Y Ong, Peter Schmid-Grendelmeier
European Urology
|
December 10, 2009
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Hans-Peter Schmid, Daniel S Engeler
The Journal of Clinical Psychiatry
|
July 20, 2006
History of trauma in people with schizophrenia predicts need for seclusion and restraint
Tilman Steinert, Peter Schmid, Gabriele Bergbauer
Page
of 63
Search research articles
Search
Showing results (21-30 of 629) with videos related to
Sort By:
Page
of 63
European Urology
|
December 22, 2011
Words of wisdom. Re: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
Hans-Peter Schmid, Robert Theiler
The New England Journal of Medicine
|
April 15, 2026
Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply
Sara M Tolaney, Peter Schmid
The New England Journal of Medicine
|
May 4, 2022
Pembrolizumab in Early Triple-Negative Breast Cancer. Reply
Peter Schmid, Javier Cortes, Rebecca Dent
Current Cancer Drug Targets
|
February 9, 2017
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Karen O'Leary, Alice Shia, Peter Schmid
The New England Journal of Medicine
|
March 12, 2025
Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. Reply
Peter Schmid, Xuan Zhou, Rebecca Dent
The New England Journal of Medicine
|
June 25, 2020
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply
Peter Schmid, Rebecca Dent, Joyce O'Shaughnessy
Translational Andrology and Urology
|
January 28, 2016
Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
Johannes M Wolff, Hans-Peter Schmid
Immunology and Allergy Clinics of North America
|
November 26, 2016
Allergic Skin Diseases
Peck Y Ong, Peter Schmid-Grendelmeier
European Urology
|
December 10, 2009
Words of wisdom. Re: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
Hans-Peter Schmid, Daniel S Engeler
The Journal of Clinical Psychiatry
|
July 20, 2006
History of trauma in people with schizophrenia predicts need for seclusion and restraint
Tilman Steinert, Peter Schmid, Gabriele Bergbauer
Page
of 63